TekCyte enters the second quarter of 2025 with accelerating activity across our technology portfolio, commercial partnerships and contract services. The year ahead will be shaped by global collaborations, clinical translation milestones, and the continued development of BIOINVISIBLE™ – our market-leading low-fouling, anti-infection coating technology.
Our technologies are gaining recognition across medical, industrial and research sectors, with increasing engagement from manufacturers, key opinion leaders and innovators seeking advanced surface solutions. We’re working at pace to deliver coatings that offer both clinical impact and commercial value.
BIOINVISIBLE™: Showcasing impact in medical applications
BIOINVISIBLE™ continues to demonstrate its potential to address one of healthcare’s most persistent challenges: implant-associated infections. Originally developed for titanium surfaces, the coating has now proven effective on polyurethane – a critical step forward, given the prevalence of polymer-based implants and devices such as catheters, vascular grafts and pelvic/hernia mesh.
The performance of BIOINVISIBLE™ in reducing bacterial adhesion and biofilm formation positions it as a high-value innovation for orthopaedic, dental, urological and vascular applications. Biofilm-related infections, such as prosthetic joint infections, represent a growing cost burden globally, and manufacturers are actively seeking technologies to improve patient outcomes while reducing clinical risk.
TekCyte is progressing active discussions with several global orthopaedic manufacturers. These include one of the world’s top three companies in the field. TekCyte CEO Tony Simula also attended the AAOS (American Academy of Orthopaedic Surgeons) annual meeting in March to meet directly with suppliers, regulatory experts and decision-makers.
To support these pathways, TekCyte has secured new capital and is initiating laboratory and animal studies to strengthen our evidence base. These studies are expected to begin in the second half of 2025 and will underpin the next phase of product evaluation and co-development.
BIOINVISIBLE™ in research and drug discovery settings
TekCyte is working with several suppliers of advanced analytical instruments and disposable products used in research and drug discovery applications. In collaboration with our industry partners, we aim to develop products that can improve the accuracy and sensitivity of testing instruments used for the screening of new drugs and therapies, for use in treating a range of medical conditions. Our coatings can help facilitate the search for new treatments that may one day make a difference for patients.
BIOINVISIBLE™ in industrial and environmental settings
Beyond healthcare, the versatility of BIOINVISIBLE™ is creating new pathways in industrial applications. In collaboration with A/Prof Jingwei Hou (University of Queensland), TekCyte has demonstrated that the coating reduces fouling and improves flow rates in filtration membranes used for both water treatment and dairy protein processing.
This work has led to a collaboration with a New Zealand-based membrane manufacturer. Additional testing is scheduled to commence in Q2 2025 and could pave the way for commercial adoption in the food and water sectors.
CYPATCH licensing marks translational success
TekCyte’s coating capabilities were highlighted in 2024 when Cynata Therapeutics (ASX: CYP) acquired the rights to our CYPATCH wound-healing coating. This followed a successful clinical trial, where the technology showed promising results with Cynata’s stem cell, Cymerus®, in accelerating wound repair in patients with diabetic-related foot ulcers (DFRU). The deal underscores TekCyte’s strength in advancing surface technologies from the lab bench to clinical application. More on this milestone is available here.
Supporting innovation through contract services
TekCyte’s contract services continue to grow as medtech companies look to fast-track development and meet clinical manufacturing requirements. Our facilities support a wide range of coating services, including production for preclinical and Phase I human clinical trials.
With a track record across multiple human clinical manufacturing campaigns, we provide a trusted environment for innovators looking to transfer their processes from the lab to a cleanroom environment suitable for Phase 1 clinical manufacture. From academic spin-outs to emerging biotech ventures, TekCyte is positioned to help turn complex ideas into manufacturable, regulatory-ready products. More information on our service offering is available here.
Looking forward
TekCyte, now in its eighth year of operation, continues to grow with deep technical capability and a clear commercial focus. We are delivering coating technologies that meet critical needs in infection prevention, performance enhancement and translational science. Through partnerships, scientific rigour and a solutions-driven mindset, we remain committed to supporting our partners in bringing better products to market.
If you’re a medtech innovator or manufacturer looking for coating solutions with proven performance and a path to scale, we welcome the opportunity to connect.
